^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RNF43 (Ring Finger Protein 43)

    i
    Other names: RNF43, Ring Finger Protein 43, RING-Type E3 Ubiquitin Transferase RNF43, E3 Ubiquitin-Protein Ligase RNF43, RING Finger Protein 43, EC 2.3.2.27, RNF124
    18d
    Evaluation of Indigo Naturalis Prepared Using a Novel Method: Anti-Inflammatory Activities Against Colonic Cancer Cell Lines. (PubMed, Mediators Inflamm)
    The possible mechanism of NIN on UC could be explained starting from the inflammation-cancer transformation. Furthermore, comprehensive research is expected between inflammation and cancer development.
    Preclinical • Journal
    |
    RNF43 (Ring Finger Protein 43) • IL1B (Interleukin 1, beta) • MUC2 (Mucin 2) • AXIN2 (Axin 2) • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    23d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    1m
    Immunological and molecular insights into acinar-ductal metaplasia and atypical flat lesions as precursor lesions of pancreatic ductal adenocarcinoma. (PubMed, J Exp Clin Cancer Res)
    Our study highlights the unique immunological and stromal features of AFL. Moreover, reinforcing their potential as precursor lesions, ADM and AFL exhibit variable alterations in the genes that have a critical role in PDAC carcinogenesis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • RNF43 (Ring Finger Protein 43) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    KRAS G12D • KRAS G12
    1m
    RSPO4 exerts tumor suppression through antagonizing canonical and non-canonical Wnt signaling. (PubMed, Int J Biol Sci)
    Mechanistically, RSPO4 exerted suppressive effects on Wnt signaling in an LGR4/5- and ZNRF3- dependent manner, through promoting LRP6 degradation and ZNRF3 stabilization. Our study revealed a novel role of RSPO4 as a tumor suppressor through antagonizing Wnt signaling, which provides important implications for development of diagnostic biomarkers and targeted therapy.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4) • RSPO1 (R-Spondin 1) • ZNRF3 (Zinc And Ring Finger 3)
    2ms
    Bioinformatic Analysis of RNF43 and Its Co-expressors As Prognostic Biomarkers for Gastric Cancer. (PubMed, Cureus)
    Moreover, overexpression of both RNF43 and HUNK was associated with prolonged OS compared to the overexpression or unaltered expression of HUNK alone. Conclusion Collectively, these results suggest RNF43 and AXIN2 as favorable prognostic factors and HUNK as a poor prognostic factor and therapeutic target for patients with GC.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • AXIN2 (Axin 2) • ZNRF3 (Zinc And Ring Finger 3)
    2ms
    Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis. (PubMed, Gut)
    RNF43 is a CRC predisposition gene, but risks are moderate, the reported polyposis phenotype is often absent and molecular phenocopies can occur. N-terminal germline RNF43 variants confer higher risk, although weak effects of C-terminal variants cannot be excluded. Genetic testing and patient management should incorporate these factors.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • SFRP4 (Secreted frizzled-related protein 4) • ZNRF3 (Zinc And Ring Finger 3)
    2ms
    Epithelial WNT secretion drives niche escape of developing gastric cancer. (PubMed, Mol Cancer)
    Gastric tumors can bypass niche dependence by acquiring KRAS-MAPK-SMAD2/3-driven epithelial WNT secretion. Targeting this axis-through MAPK inhibition, SMAD2/3 blockade, or suppression of WNT secretion-may represent a therapeutic vulnerability in gastric cancer and other KRAS-high malignancies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • WNT7B (Wnt Family Member 7B) • WNT2 (Wnt Family Member 2) • ZNRF3 (Zinc And Ring Finger 3)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • KRAS G12D • KRAS G12 • KRAS amplification
    3ms
    Cystic tumors of the pancreas: Current perspectives on diagnosis and management. (PubMed, World J Gastroenterol)
    Additionally, we emphasize the urgent need for cost-effective, accurate, and accessible diagnostic pathways. A more refined risk stratification approach is essential to optimize outcomes, reduce healthcare waste, and improve the quality of life for patients with pancreatic cystic lesions.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • RNF43 (Ring Finger Protein 43) • CEACAM5 (CEA Cell Adhesion Molecule 5) • GNAS (GNAS Complex Locus)
    |
    KRAS mutation
    3ms
    MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. (PubMed, Nature)
    Together, our data provides clear insight into the mechanisms underpinning resistance to MAPK targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • RNF43 (Ring Finger Protein 43)
    |
    KRAS mutation • BRAF mutation
    3ms
    WNK kinase regulates plasma membrane levels of the WNT inhibitor RNF43. (PubMed, bioRxiv)
    These findings define a new regulatory axis linking the pro-WNT activity of WNKs to RNF43/ZNRF3-mediated feedback inhibition. Targeting WNK now offers a novel therapeutic strategy to restore WNT pathway control in cancers with RSPO fusions or RNF43 mutations.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • ZNRF3 (Zinc And Ring Finger 3)
    3ms
    Brd4 BD1 Domain Antagonism of MS436 Preserves Blood-Brain Barrier Integrity via Rnf43/β-Catenin Signaling Pathway. (PubMed, Adv Sci (Weinh))
    Crucially, opposing BBB effects of domain-specific BET antagonism: the BD2 antagonist RVX208 disrupt the BBB, whereas the BD1 antagonist MS436 significantly reduces leakage and improves neurological outcomes, revealing therapeutic potential is demonstrated...This defines a novel Brd4 BD1/Rnf43/β-catenin axis essential for BBB integrity. The findings establish Brd4 BD1 inhibition as a novel BBB-protective strategy and position MS436 for repurposing in cerebrovascular diseases, necessitating reevaluation of domain-specific BET targeting for neurovascular pathologies.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BRD4 (Bromodomain Containing 4)
    3ms
    A set cover algorithm identifies minimal circulating tumour DNA sequencing targets for colorectal cancer detection. (PubMed, Sci Rep)
    Our pipeline enables compact panel design without compromising sample coverage. This enables higher throughput, greater sequencing depth, and lower costs per-sample in early colorectal cancer detection from cell-free DNA.
    Journal • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RNF43 (Ring Finger Protein 43) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ACVR2A (Activin A Receptor Type 2A)